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Background: Human bone marrow mesenchymal stem cells (hBMSCs) are multipotent cells that can differentiate
into a variety of cell types. Elevated expression of peroxisome proliferator-activated receptor-γ (PPARγ) promotes
the adipogenic differentiation of hBMSCs, and reduces their osteogenic differentiation. MicroRNAs (miRNAs) have
been shown to play important roles in the regulation of hBMSCs differentiation. Because bioinformatic analysis has
indicated that PPARγ is a candidate target of miR-548d-5p, the aim of this study was to assess the impact of
miR-548d-5p on the dexamethasone-induced adipogenic differentiation of hBMSCs.
Methods: A quantitative RT-PCR (qRT-PCR) assay was used to compare miR-548d-5p expression levels in
dexamethasone-induced hBMSCs and uninduced control cells. Oil red O staining, cellular triglyceride (TG) content,
and the mRNA and protein levels of PPARγ and CCAAT/enhancer binding protein α (C/EBPα) were used to evaluate
the adipogenic differentiation of hBMSCs. Alkaline phosphatase (ALP) activity and levels of osteocalcin (OCN) and
Runx2 were used to evaluate the osteogenic potential of hBMSCs.
Results: Compared with untreated cells, miR-548d-5p expression levels were downregulated during
dexamethasone-induced adipogenic differentiation of hBMSCs. In contrast to the profuse Oil Red O staining in the
cytoplasm of dexamethasone + scrambled miRNA-treated cells, there was limited staining in the cytoplasm of
dexamethasone +miR-548d-5p-treated cells, indicating the absence of adipocytes. Moreover, compared with
scrambled miRNA-treated cells, treatment with miR-548d-5p suppressed cellular levels of PPARγ and C/EBPα mRNA
and protein, and cell TG content (P < 0.05). In contrast, compared with scrambled miRNA-treated cells, cellular levels
of OCN and Runx2 mRNA and protein, as well as ALP activity, were significantly higher in miR-548d-5p-treated
cells (P < 0.05). Western blot and luciferase reporter assays confirmed that miR-548d-5p directly targeted the
3′-untranslated region of PPARγ.
Conclusions: miR-548d-5p is downregulated during dexamethasone-induced adipogenic differentiation of hBMSCs.
By directly targeting and downregulating PPARγ, miR-548d-5p suppresses the dexamethasone-induced adipogenic
differentiation of hBMSCs and enhances their osteogenic potential. Our findings suggest that miR-548d-5p has
potential in the treatment of corticosteroid-induced osteonecrosis of the femoral head.
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Human bone marrow mesenchymal stem cells (hBMSCs)
are multipotent cells that can differentiate into a variety of
cell types, including adipocytes, osteoblasts, and chondro-
cytes [1-3]. While hBMSCs differentiation is known to be
modulated by a number of regulatory factors and complex
signaling pathways [4,5], it remains largely uncharacte-
rized. A variety of human diseases, such as osteoporosis,
age-related bone loss, and osteonecrosis, have been linked
to imbalances between adipogenic and osteogenic differ-
entiation of hBMSCs [6,7]. For example, osteonecrosis of
the femoral head (ONFH), resulting from increased in-
traosseous pressure and ischemia in the femoral head, is
frequently observed in patients treated with elevated doses
of corticosteroids [8].
Treatment of hBMSCs with pharmacological doses of
glucocorticoids increases intracellular triglycerides and
promotes adipogenic differentiation [9], a complex pro-
cess involving a coordinated cascade of multiple tran-
scription factors and signaling pathways. Induction of the
adipogenic genes that ultimately give rise to the phenotype
of terminally differentiated adipocytes is co-ordinated
by CCAAT/enhancer binding protein α (C/EBPα) and
peroxisome proliferator-activated receptor-γ (PPARγ)
[10,11], a member of the ligand-activated nuclear recep-
tor superfamily of transcription factors [10-12]. Ele-
vated cellular levels of PPARγ promote the adipogenic
differentiation of hBMSCs and inhibit their osteogenic
differentiation, increasing cellular lipid levels and de-
creasing bone formation [13]. Consistent with this,
down-regulation of PPARγ inhibits the adipogenic dif-
ferentiation of rabbit BMSCs, and promotes their os-
teogenic differentiation potential, an effect that would
potentially antagonize corticosteroid-induced ONFH
[14,15].
MicroRNAs (miRNAs) are small non-coding RNAs
that regulate gene expression by targeting complemen-
tary sequences located primarily within the 3′-untrans-
lated regions (UTRs) of their target mRNAs [16-18].
miRNAs play well-characterized pivotal roles in a variety
of biological processes, including cell fate determination
in embryonic stem cells, cell proliferation, apoptosis, dif-
ferentiation, morphogenesis, and carcinogenesis [19-22].
Additionally, miRNAs have been shown to participate in
the regulation of adipogenic and osteogenic differenti-
ation in hBMSCs [23-25].
Although bioinformatic analysis has implicated PPARγ
as a candidate target of miR-548d-5p, the effect of miR-
548d-5p on glucocorticoid-induced adipogenic differen-
tiation of hBMSCs remains obscure. In the present
study, we measured cellular levels of miR-548d-5p dur-
ing dexamethasone-induced adipogenic differentiation
of hBMSCs, and assessed the effect on this process of
treatment of hBMSCs with miR-548d-5p.Materials and methods
Cell culture
hBMSCs were purchased from Cyagen Biosciences Co.
Ltd. (Guangzhou, China), cell identification by flow cy-
tometry revealed that hBMSCs were positive for CD29,
CD44 and CD105, negative for CD34 and CD45. They
were cultured in low glucose complete DMEM culture
medium (containing 10% fetal bovine serum, 100 kU/mL
penicillin, 100 mg/L streptomycin, 50 mg/L vitamin C,
1 mmol/L L-glutamine, and 20 mmol/L HEPES) and in-
cubated in a humidified atmosphere of 5% CO2 at 37°C.
The third passage hBMSCs were used in this study.Dexamethasone-induced adipogenic differentiation
Dexamethasone was added to hBMSCs medium which
requiring dexamethasone induction at a final concen-
tration of 10−7 mol/L. The same concentration of de-
xamethasone was added to new medium each time it
was replaced.
miRNA transfection
The miR-548d-5p agomir (GMR-miR™ microRNA-548d-
5p agomir) used in this study was synthesized by Shanghai
GenePharma Co. Ltd. (Shanghai, China). Prior to transfec-
tion, hBMSCs were plated in six-well plates at a density of
1.5 × 105 cells/well. Once cells reached ~50% confluence,
transient transfections were conducted using Lipofecta-
mine™2000 (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions, each well was transfected
with 50nmol miR-548d-5p agomir.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from cells using a Total RNA
Kit (OMEGA, Norcross, GA, USA), according to the ma-
nufacturer’s instructions. cDNA was synthesized using the
RevertAid First Strand cDNA (Thermo Fisher Scientific,
Waltham, MA, USA). qRT-PCR was carried out using
SYBR Green I (TaKaRa, Dalian, China), and gene expres-
sion levels were normalized to GAPDH. All experiments
were performed in triplicate. To verify mature miRNA
expression levels, qRT-PCR was performed using a
High-Specificity miR-548d-5p qRT-PCR Detection Kit
(Stratagene Corp, La Jolla, CA, USA) in conjunction
with an ABI 7500 thermal cycler, according to the manu-
facturer’s recommendations. The miR-548d-5p expression
level was normalized to U6 small nuclear RNA (U6
snRNA), and measured using the comparative Ct (2-ΔCt)
method. The primers for miR-548d-5p were 5’GTCGT
ATCCAGTGCAGGGTCCGAGGTATT CGCACTGGAT
ACGACGGCAAAA3’ (RT primer), 5’TCCGAAAAAG
TAATTGTGGT 3’ (forward), 5’GTGCAGGGTCCGAG
GT 3’(reverse). The primers for U6 were 5’GTCGTATC
CAGTGCAGGGTCCGAGGTATTCGCACTGGATACGA
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Oil red O staining
Oil red O staining was conducted at day 14 following
dexamethasone treatment. Cells were washed twice with
PBS and fixed with 10% formalin for 10 min at room
temperature. After fixation, cells were stained with fil-
tered oil red O solution for 1h at room temperature.
Determination of cellular triglyceride (TG) content
Cellular TG content was determined using a Triglyceride
Determination Kit (Applygen, Beijing, China) at day 14
of dexamethasone treatment. hBMSCs were collected,
with a final cell density of 1 × 106 cell/mL in each group.
After centrifugation at 1000 r/min for 10 min, cells were
washed twice with PBS and lysed with 1% TritonX-100
for 30 min. Then, 3 μL of cytochylema and 300 μL of
working solution were added into 96-well plates, mean-
while set blank wells and calibration wells. Cells were incu-
bated at 37°C for 5 min after blending, and the absorbance
values were measured at a wavelength of 500 nm.
ALP activity assay
ALP activity was determined using an enzyme-linked
immunosorbent assay (ELISA) test kit (R&D Systems,
Minneapolis, MN, USA) at day 6 of culture. hBMSCs
were suspended in 1 mL buffer solution and centrifuged
at 15 000 r/min for 15 min at 4°C after repeated freezing-
thawing treatment to lyse the cells. Set standard wells on
the ELISA plates and prepared standard solution. Forty
microliters of diluent and 10 μL of supernatant were
added into sample wells, and incubated at 37°C for 30 min
after blending, meanwhile set blank wells. After washing 3
times, 50 μL of horseradish peroxidase was added into the
sample wells, and incubated at 37°C for 30 min. After
washing for three times, 100 μL of chromogenic solution
was added and incubated at 37°C for 15 min. Finally,
50 μL of stop solution was added and absorbance values
were measured at a wavelength of 450 nm.
Dual-luciferase assay
By bioinformatic analysis using TargetScan (http://www.
targetscan.org/) and miRBase (http://www.mirbase.org/),
we suggest that PPARγ as a candidate target of miR-
548d-5p. Human PPARγ 3′-UTR fragments containing
putative binding sites for miR-548d-5p were amplified
by PCR from human genomic DNA. Mutant PPARγ 3′-
UTRs were obtained by overlap extension PCR. The
fragments were cloned into a pmirGLO reporter vector
(Promega), downstream of the luciferase gene, to gener-
ate the recombinant vectors pmirGLO-PPARγ-Wt and
pmirGLO-PPARγ-Mut. For the luciferase reporter assay,
hBMSCs were transiently co-transfected with miRNA(miR-548d-5p agomir or scrambled negative control) and
reporter vectors (wild-type reporter vectors or mutant-type
reporter vectors), using Lipofectamine™2000 (Invitrogen,
Carlsbad, CA, USA). Luciferase activities were measured
using a Dual-Luciferase assay kit (Promega, Madison, WI,
USA) according to the manufacturer’s instructions at 48 h
post-transfection.Western blotting
Total proteins of cultured cells were extracted using
RIPA buffer containing phenylmethanesulfonylfluoride.
Protein concentration was determined using the BCA
protein assay kit (Beyotime, Haimen, China) according
to the manufacturer’s protocol. Proteins were subjected
to sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and transferred onto polyvinylidene difluoride
membranes. After blocking, the membranes were incu-
bated overnight at 4°C with diluted (1:300) primary anti-
bodies (monoclonal mouse anti-PPARγ or anti-C/EBPα
or anti-OCN or anti-Runx2; Santa Cruz Biotechnology,
Dallas, TEX, USA). Following extensive washing, the
membranes were incubated with diluted (1:3000) horse-
radish peroxidase-conjugated rabbit anti-mouse IgG
(Santa Cruz Biotechnology, Dallas, TEX, USA). Signals
were determined using a chemiluminescence detection
kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
An antibody against β-actin (Santa Cruz Biotechnology,
Dallas, TEX, USA) served as endogenous reference.
Statistical analysis
Data are presented as mean ± standard deviation. Data
processing was performed by analysis of variance. Pair-
wise comparison among groups was performed using
multiple comparisons tests. Statistical analysis was per-
formed with SPSS 17.0 software (SPSS Inc., Chicago, IL,
USA). Differences with P < 0.05 were considered statisti-
cally significant.
Results
Regulation of miR-548d-5p levels by dexamethasone
during adipogenic differentiation of hBMSCs
Based on studies showing that supraphysiological doses
of glucocorticoids induce the differentiation of hBMSCs
into adipocytes, 10−7 mol/L of dexamethasone was cho-
sen as the effective dose [9]. Compared with non-induced
(Blank) cells, hBMSCs cultured in the presence of de-
xamethasone had higher cytoplasmic oil red O staining
(Figure 1a) and higher TG content (P < 0.05; Figure 1b)
after 14 days, and decreased levels on day 6 of ALP,
an early marker of osteogenic differentiation (P < 0.05;
Figure 1c). Moreover, relative to cells in the Blank group,
dexamethasone-treated hBMSCs had lower levels of miR-
548d-5p (day 7 and day 14, P < 0.05; Figure 1d) and
Figure 1 Dexamethasone induces adipogenic differentiation of hBMSCs and downregulates miR-548d-5p expression. Blank, non-induced
hBMSCs; Dexamethasone-induced, hBMSCs induced with dexamethasone. (a) Oil red O staining showing more adipocytes were detectable in the
cytoplasm of the cells in the dexamethasone-induced group than the Blank group at day 14. (b) TG content was measured at day 14. (c) ALP
activity was measured using ELISA at day 6. (d) Expression levels of miR-548d-5p in the Dexamethasone-induced group and Blank group
were measured by qRT-PCR at day 7 and day 14. U6 was used as an internal control. (e,f) qRT-PCR analysis of Runx2, OCN, PPARγ, and
C/EBPα. The data were normalized to GAPDH. (g,h) Runx2, OCN, PPARγ, and C/EBPα protein levels were detected by Western blotting
analysis, β-actin was used as a reference.
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Figure 1e, 1g). Furthermore, qRT-PCR (day 6, P < 0.05;
Figure 1f) and western blotting (day 6, Figure 1h) showed
that levels of the adipogenic transcription factors
PPARγ and C/EBPα were higher in the dexamethasone-
induced group than in the Blank group. Collectively,
these results confirm the induction by dexamethasone
of adipogenic differentiation in hBMSCs, and its in-
hibition of osteogenic differentiation in these cells. The
induction of miR-548d-5p expression in dexamethasone-
treated hBMSCs suggested to us that miR-548d-5p had a
role in the regulation of their adipogenic differentiation.Overexpression of miR-548d-5p suppresses
dexamethasone-induced adipogenic differentiation of
hBMSCs
We next sought to elucidate the role of miR-548d-5p
during dexamethasone-induced adipogenic differenti-
ation of hBMSCs by transfection studies using the miR-
548d-5p agomir. Cells were divided into four groups,
namely: Blank Group: untransfected, uninduced hBMSCs;
Control Group: untransfected hBMSCs induced with de-
xamethasone; NC Group: scrambled agomir-transfected
hBMSCs induced with dexamethasone; and miR-548d-5p
Group: miR-548d-5p agomir-transfected hBMSCs induced
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548d-5p levels were eight-fold higher in the miR-548d-5p
Group compared with the Control and NC groups (day 2,Figure 2 Overexpression miR-548d-5p suppresses dexamethasone-ind
and non-induced cells; Control, non-transfected hBMSCs induced with dex
negative control and induced with dexamethasone; miR-548d-5p, cells tran
(a) Oil red O staining on day 14 of culture. (b) Mature miR-548d-5p expres
containing was measured at day 14. (d) The ALP activity in the Control and
but there were no significant differences between the miR-548d-5p and Bl
were detected by qRT-PCR analysis. The data were normalized to GAPDH. (
western blotting analysis, β-actin was used as a reference.Figure 2b). Oil red O staining assay on day 14 of induction
showed that, in contrast to cells in the Blank and miR-
548d-5p groups, in which no or few cells stained positive,uced adipogenic differentiation of hBMSCs. Blank, non-transfected
amethasone; NC, cells transfected with scrambled miR-548d-5p
sfected with miR-548d-5p agomir and induced with dexamethasone.
sion levels after transfection, U6 was used as an internal control. (c) TG
NC groups were significantly lower than in the Blank group (P < 0.05),
ank groups (P > 0.05). (e) PPARγ, C/EBPα, Runx2, and OCN mRNA levels
f) PPARγ, C/EBPα, Runx2, and OCN protein levels were detected by
Figure 3 PPARγ is a target of miR-548d-5p in hBMSCs. (a) The putative miR-548d-5p seed region in the PPARγ 3’-UTR. (b) Western blotting
analysis of PPARγ expression in transfected cells. β-actin was used as a reference. Blank, nontransfected cells; NC, cells transfected with scrambled
miR-548d-5p negative control; miR-548d-5p, cells transfected with miR-548d-5p agomir. (c) Luciferase activity determined 48 h after transfection.
Control, scrambled miRNA; miR-548d-5p, miR-548d-5p agomir; pmirGLO-PPARγ-Wt, wild-type pmirGLO-PPARγ; pmirGLO-PPARγ-Mut, mutant
pmirGLO-PPARγ. *P < 0.05 compared with the control group.
Figure 4 Expression of PPARγ abrogates the anti-dexamethasone-
induced adipogenic differentiation function of miR-548d-5p. (a)
Western blotting analysis of hBMSCs transfected with pcDNA3.1-PPARγ
lacking the 3′-UTR sequence and/or miR-548d-5p. β-actin was used as a
reference. (b) TG content was measured in hBMSCs transfected with
pcDNA3.1-PPARγ lacking the 3′-UTR sequence and/or miR-548d-5p.
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orange fat droplets in their cytoplasm (Figure 2a). Consist-
ent with this, TG content in the Blank and miR-548d-5p
groups was significantly lower than in the NC and Control
groups (day 14, P < 0.05; Figure 2c). Moreover, the higher
ALP activity in the miR-548d-5p group relative to the NC
and Control groups (day 6, P < 0.05; Figure 2d) suggested
that miR-548d-5p maintained the osteogenic potential of
hBMSCs. Compared with the NC and Control groups,
overexpression of miR-548d-5p depleted PPARγ and
C/EBPα at both the mRNA and protein levels (P < 0.05),
and increased protein levels of the osteogenic markers
Runx2 and OCN (P < 0.05) (day 6, Figure 2e, 2f). These
results indicated to us that overexpression of miR-548d-
5p suppressed the dexamethasone-induced adipogenic dif-
ferentiation of hBMSCs and supported the osteogenic
potential of these cells.
PPARγ is direct target of miR-548d-5p
Bioinformatic analysis using TargetScan and miRanda
indicated that PPARγ is a candidate target of miR-548d-
5p (Figure 3a), leading us to speculate as to whether
miR-548d-5p could directly down-regulate PPARγ ex-
pression. Western blotting assay indicated that overex-
pression of miR-548d-5p substantially decreased cellular
levels of PPARγ (Figure 3b). Consistent with this, we
found that compared with cells in the NC group, lucifer-
ase activity was reduced by cotransfection of miR-548d-
5p with the pmirGLO-PPARγ-Wt vector, but not the
pmirGLO-PPARγ-Mut vector (Figure 3c). These results
indicated that miR-548d-5p regulated PPARγ expression
by directly targeting the 3′-UTR of PPARγ.
Expression of PPARγ restores anti-dexamethasone-induced
adipogenic differentiation function of miR-548d-5p
Western blotting analysis showed that cell levels of
PPARγ were decreased in miR-548d-5p agomir-transfectedhBMSCs, but not in cells co-transfected with miR-
548d-5p agomir and PPARγ lacking the 3′-UTR se-
quence (pcDNA3.1-PPARγ) (Figure 4a). Moreover, we
found that TG content was not decreased in hBMSCs
co-transfected with pcDNA3.1-PPARγ and miR-548d-5p
agomir (Figure 4b). These results indicated that PPARγ
expression restores the anti-dexamethasone-induced adi-
pogenic differentiation function of miR-548d-5p.
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miRNAs play important roles in the regulation of
hBMSCs differentiation. miR-141 and miR-200a, for ex-
ample, have been reported to regulate osteoblast differen-
tiation by targeting the BMP-2 signaling pathway [26].
Moreover, miR-346 positively regulates hBMSCs osteo-
genic differentiation by targeting GSK-3β and activating
the Wnt/β-catenin pathway [27]. In the current study,
we found that miR-548d-5p inhibits dexamethasone-
induced adipogenesis in hBMSCs by targeting PPARγ.
Our data indicate that miR-548d-5p overexpression
down-regulated PPARγ levels by directly targeting the
3′-UTR of PPARγ mRNA. Luciferase reporter gene assays
demonstrated that this effect was largely eliminated when
bases in the PPARγ mRNA 3′-UTR targeted by miR-
548d-5p were mutated.
PPARγ is one of the most important cell-fate-defining
factors in hBMSCs. It has been shown to positively regu-
late adipogenesis [28,29], and is one of the earliest in-
duced genes in preadipocytes [30]. Consistent with this,
we found that PPARγ was induced at both the mRNA
and protein levels during dexamethasone-induced adi-
pogenesis in hBMSCs, an effect that was abrogated in
the presence of transfected miR-548d-5p. These data
indicated that miR-548d-5p overexpression suppressed
PPARγ at both the mRNA and protein levels, and in
doing so inhibited dexamethasone-induced adipogenic
differentiation.
Runx2 is a master regulator of osteogenesis in hBMSCs,
and was the first transcription factor to be shown to
be required for determination of the osteoblast lineage
[31]. Analogous to PPARγ in adipogenic differentiation,
Runx2 mediates the effects of a variety of cytokines in
determining the osteogenic differentiation of hBMSCs
[32]. We found that expression of Runx2 and OCN
were increased in the presence of miR-548d-5p, as was
the activity of ALP, which plays an important role in
the process of osteoblast differentiation of hBMSCs [33].
Collectively, these data implied that miR-548d-5p pro-
motes the osteogenic potential of dexamethasone-induced
hBMSCs.
In conclusions, miR-548d-5p is downregulated dur-
ing dexamethasone-induced adipogenic differentiation
of hBMSCs. miR-548d-5p inhibits steroid-induced ad-
ipogenesis of hBMSCs and maintains their osteogenic
potential by targeting PPARγ. Our findings suggest
that miR-548d-5p has potential in the treatment of
corticosteroid-induced osteonecrosis of the femoral head.Abbreviations
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